Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCRTR2 | O43614 | 14/20 | 0.47 |
| ▸ | HCRTR1 | O43613 | 13/20 | 0.47 |
| ▸ | P2RX7 | Q99572 | 4/20 | 0.46 |
| ▸ | TP53 | P04637 | 1/20 | 0.44 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.44 |
| ▸ | EHMT2 | Q96KQ7 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30748727 | 1.00 | HCRTR2 (0.47) | HCRTR2HCRTR1P2RX7TP53MDM2 | |
| SCHEMBL8776162 | 0.82 | TP53 (0.45) | HCRTR2HCRTR1P2RX7TP53MDM2 | |
| SCHEMBL8776158 | 0.82 | TP53 (0.45) | HCRTR2HCRTR1P2RX7TP53MDM2 | |
| SCHEMBL23513155 | 0.76 | CYP3A4 (0.50) | HCRTR2HCRTR1P2RX7TP53MDM2 | |
| SCHEMBL2265479 | 0.76 | HCRTR2 (0.50) | HCRTR2HCRTR1TP53MDM2EHMT2 | |
| SCHEMBL7407552 | 0.76 | HCRTR2 (0.50) | HCRTR2HCRTR1TP53MDM2EHMT2 | |
| SCHEMBL22443716 | 0.74 | TP53 (0.46) | HCRTR2HCRTR1P2RX7TP53MDM2 | |
| SCHEMBL22201131 | 0.74 | CHRM2 (0.56) | HCRTR2HCRTR1TP53MDM2EHMT2 | |
| SCHEMBL22190389 | 0.74 | CHRM2 (0.56) | HCRTR2HCRTR1TP53MDM2EHMT2 | |
| SCHEMBL22443715 | 0.74 | TP53 (0.46) | HCRTR2HCRTR1P2RX7TP53MDM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250304571-A1 | BIOLOGICALLY ACTIVE COMPOUNDS AND METHODS THEREOF | SUZHOU KEEN THERAPEUTICS CO., LTD. (CN) | 2025-10-02 | — | — | US | disclosed |
| EP-4565588-A1 | BIOLOGICALLY ACTIVE COMPOUNDS AND METHODS THEREOF | Suzhou Keen Therapeutics Co., Ltd. (CN) | 2025-06-11 | — | — | EP | disclosed |
| WO-2023241620-A1 | BIOLOGICALLY ACTIVE COMPOUNDS AND METHODS THEREOF | SUZHOU KEEN THERAPEUTICS CO., LTD. (CN) | 2023-12-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250304571-A1 | BIOLOGICALLY ACTIVE COMPOUNDS AND METHODS THEREOF | VHL, BRCA1, TERT | HCRTR2 4051/4885HCRTR1 2961/4885P2RX7 1286/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.